# Investigator-initiated Phase I Exploratory Clinical Study of the Safety, Tolerability, and Efficacy of BST02 Injection in the Treatment of Locally Advanced/Metastatic Liver Cancer

> **NCT06173726** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **BioSyngen Pte Ltd** · enrollment: 6 (estimated)

## Conditions studied

- Locally Advanced/Metastatic Liver Cancer

## Interventions

- **BIOLOGICAL:** BST02 Injection

## Key facts

- **NCT ID:** NCT06173726
- **Lead sponsor:** BioSyngen Pte Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-12-05
- **Primary completion:** 2026-12-05
- **Final completion:** 2026-12-05
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2023-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06173726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06173726, "Investigator-initiated Phase I Exploratory Clinical Study of the Safety, Tolerability, and Efficacy of BST02 Injection in the Treatment of Locally Advanced/Metastatic Liver Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06173726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*